Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos - PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors

Industrial Health

Volumn 36, Issue 1, 1998, Pages 52-56

  Kitamura, Fumihiko ^a   Araki, Shunichi ^a   Tanigawa, Takeshi ^a   Miura, Hirotaro ^b   Akabane, Hisamasa ^b   Iwasaki, Ryu ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

^c Mitsubishi Kagaku Bio Clin Labs   (Japan)

Author keywords

Asbestos; Malignant mesothelioma; p53 suppressor gene; Paraffin embedded tissue; PCR SSCP analysis; ras oncogene; Sequencing analysis

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; ASBESTOSIS; CLINICAL ARTICLE; DNA DAMAGE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; ONCOGENE RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEQUENCE HOMOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0031936707     PISSN: 00198366     EISSN: None     Source Type: Journal    
DOI: 10.2486/indhealth.36.52     Document Type: Article

References (26)

1. Harris CC (1991) Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 51, 5023s-44s.
2. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P (1994) Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264, 1317-9.
3. 1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 53, 51-5.
4. 1 induces the transversion of G to T in codon 249 p53 tumor suppressor gene in human hepatocytes, Proc Natl Acad Sci USA 90, 8586-90.
5. Ozturk M, Collaborators (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338, 1356-9.
6. Hollstein M, Marison M-J, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, Hontesano R (1994) p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15, 1-3.
7. Taylar JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M (1994) p53 mutation hotspot in radon-associated lung cancer. Lancet 343, 86-7.
8. Vahakangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, Harris CC (1992) Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339, 576-80.
9. Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the north western cape province. Brit J Industr Med 17, 260-71.
10. Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM (1996) Asbestos induces apoptosis of human and rabbit pleural mesothelioma cells via reactive oxygen species. J Clin Invest 98, 2050-9.
11. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma, Cancer Res 54, 5547-51.
12. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJP, Testa JR (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesothelioma, Proc Natl Acad Sci 92, 10854-8.
13. Metcalf RA, Welsh JA, Bennett WP, seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, et al. (1992) p53 and Kirstenras mutations in human mesothelioma cell lines, Cancer Res 52, 2610-5.
14. Cote RJ, Jhanwar SC, Novick S, Pellicer A (1991) Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51, 5410-6.
15. Janssen WJ, Lyon J, Steenvorden ACM, Seliger H, Artram CR (1987) Concurrent mutations in two different ras genes in acute myeloid leukemias, Nucleic Acids Res 15, 5669-80.
16. Cristaudo A, Vivaldi A, Sensales G, Guglielmi G, Ciancia E, Elisei R, Ottenga F (1995) Molecular biology studies on mesothelioma tumor samples: Preliminary data on H-ras, P21, and SV40. J Environ Ptho Toxico and Oncology 14, 29-34.
17. Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N (1997) Absence of p53 mutations in malignant mesothelioma. Am J Respir Cell Mol Biol 16, 9-13.
18. Goelz SE, Hamilton SR, Vogelstein B (1985) Purification of DNA formaldehyde fixed and paraffin embedded human tissue. Biochemical and biophysical communications 130, 118-26.
19. Saiki PD, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase, Science 239, 487-91.
20. Bos JL (1989) ras oncogenes in human cancer A review. Cancer Res 49, 4682-9.
21. Hayashi K (1991) PCR-SSCP: A simple and sensitive method for detection of mutations in the genomic DNA, PCR methods and aplicatuons. 1, 34-8.
22. Hayashi K, Yandell DW (1993) How sensitive is PCR-SSCP? Human Mutation 2, 338-46.
23. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R (1992) p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking, Cancer Res 52, 734-6.
24. Reddy EP, Skalka AM, Curran T (1998) The oncogene handbook. Elsevier science publishing company, Inc, New York.
25. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K (1995) Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 55, 2981-3.
26. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC (1993) A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. Hum Genet 91, 25-30.